Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

PURPOSE: We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pe...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C., Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Wolchok, Jedd D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2016
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5070547/
https://ncbi.nlm.nih.gov/pubmed/26951310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.0391
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg